Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02712905

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

Sponsor: Incyte Corporation

Conditions Solid Tumors and Hematologic Malignancy

Interventions INCB059872 all-trans retinoic acid (ATRA) azacitidine nivolumab

Updated 19 times since 2017 Last updated: Oct 20, 2025 Started: May 5, 2016 Primary completion: Apr 14, 2022 Completion: Apr 14, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic Business Decision

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

Listed as NCT02712905, this PHASE1/PHASE2 trial focuses on Solid Tumors and Hematologic Malignancy and remains terminated or withdrawn. Sponsored by Incyte Corporation, it has been updated 19 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

19 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE1/PHASE2
Sep 2025 — Dec 2025 [monthly]

Terminated PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jul 2023 — Jul 2024 [monthly]

Terminated PHASE1_PHASE2

▶ Show 14 earlier versions

Jul 2022 — Jul 2023 [monthly]

Terminated PHASE1_PHASE2

Status: Active Not Recruiting → Terminated
Feb 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Terminated → Active Not Recruiting
Jan 2021 — May 2021 [monthly]

Terminated PHASE1_PHASE2
Aug 2020 — Jan 2021 [monthly]

Terminated PHASE1_PHASE2

Status: Recruiting → Terminated
Sep 2019 — Aug 2020 [monthly]

Recruiting PHASE1_PHASE2
Mar 2019 — Sep 2019 [monthly]

Recruiting PHASE1_PHASE2
Aug 2018 — Mar 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1_PHASE2
Feb 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2
Dec 2017 — Feb 2018 [monthly]

Recruiting PHASE1_PHASE2
May 2017 — Dec 2017 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — May 2017 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Incyte Corporation

Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Birmingham, United States , Brussels, Belgium , Buffalo, United States , Chicago, United States , Houston, United States , Kansas City, United States , La Jolla, United States , Los Angeles, United States , Nashville, United States and 4 more locations